<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129662">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414114</url>
  </required_header>
  <id_info>
    <org_study_id>KAI-4169-005</org_study_id>
    <nct_id>NCT01414114</nct_id>
  </id_info>
  <brief_title>Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects</brief_title>
  <official_title>A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KAI Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV)
      administration of KAI-4169 in the treatment of secondary hyperparathyroidism (SHPT) in
      hemodialysis subjects with chronic kidney disease-mineral and bone disorder (CKD-MBD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in iPTH from baseline during the efficacy period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 30% reduction in iPTH from baseline during the efficacy period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with iPTH ≤ 300 pg/mL during the efficacy period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corrected calcium and phosphorus from baseline during the efficacy period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>KAI-4169</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-4169</intervention_name>
    <description>KAI-4169 will be administered IV thrice weekly for 12 weeks. Dose will be titrated to effect.</description>
    <arm_group_label>KAI-4169</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects provides written informed consent

          -  Screening intact PTH (iPTH) ≥350 pg/mL and corrected calcium ≥ 8.5 mg/dL

          -  Hemoglobin ≥ 8.5 g/dL

          -  Serum transaminases (ALT or SGPT, AST or SGOT) less than 2.5 times the upper limit of
             normal

          -  Adequate hemodialysis three times per week

        Exclusion Criteria:

          -  History or symptomatic ventricular dysrhythmias

          -  History of angina pectoris or congestive heart failure

          -  History of myocardial infarction, coronary angioplasty, or coronary artery bypass
             grafting within the past 6 months

          -  History of or treatment for seizure disorder within the last 12 months

          -  Postdialysis systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 90 mmHg

          -  Serum magnesium below the lower limit of normal at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Bell, MD</last_name>
    <role>Study Director</role>
    <affiliation>KAI Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 8, 2015</lastchanged_date>
  <firstreceived_date>August 9, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>July 8, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trial, Phase 2</keyword>
  <keyword>Renal Dialysis</keyword>
  <keyword>Secondary Hyperparathyroidism</keyword>
  <keyword>Chronic kidney disease-mineral and bone disorder</keyword>
  <keyword>Parathyroid hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
